Replies to post #6599 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Smile86, I agree that ANIP will do well without Libigel. However I disagree that it is dead in the water or that transference is an issue.

According to this article you would need to use 100 times the minimum dosage of Libigel to generate the same levels of potential transference generated by males using their minimum dosage. Safety concerns were addressed under the FDA SPA which gave them a path towards approval.

Transdermal testosterone gels were introduced in the U.S. in 2000. Two gels are approved in the U.S. for men: AndroGel and Testim (1%). These topically applied products are a favorable and popular mode of testosterone replacement therapy. The usual starting dose for testosterone gels in men is 50 to 60 mg per day. Survey data on the prescribing of testosterone by U.S. physicians in 2009 found that approximately 4 million prescriptions for estrogen/androgen oral medications, compounded testosterone, or brand testosterone approved for use in men were written off-label for women.3 Since the commercially available dosages are too strong for women, female patients typically are treated with testosterone compounded at a dosage of 0.5 to 2 mg per day.

https://www.uspharmacist.com/article/androgen-therapy-in-women

Personally I see Abbvie co-promoting on Libigel under a new name since it will do more than just treat HSDD. If ANIP secures the patent for CV and Breast Cancer reduction, Abbvie will buyout ANIP.

JMHO